QALSODY (tofersen injection) approved as a treatment for SOD1-ALS in Canada with Conditions
March 03, 2025
Health Canada has approved QALSODY (tofersen injection) under a Notice of Compliance with Conditions (NOC/c) for the treatment of ALS in adults who have a pathogenic variant (also known as a mutation) in the superoxide dismutase 1 (SOD1) gene. This…
Continue reading